Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis [0.03%]
戈利木单抗：治疗类风湿性关节炎、强直性脊椎炎和银屑病性关节炎的新一代抗TNF-α的人源化单克隆抗体
Jonathan Kay,Mahboob U Rahman
Jonathan Kay
Introduction: The introduction of tumor necrosis factor-alpha (TNF-alpha) inhibitors represented a significant advance in the management of rheumatoid arthritis (RA) and other chronic inflammatory diseases. Although three...
Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection [0.03%]
艾特拉韦林(TMC125)治疗HIV-1感染的临床证据分析
Hans-Jürgen Stellbrink
Hans-Jürgen Stellbrink
Introduction: Etravirine is a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) specifically designed to suppress the replication of viruses resistant to the three currently approved NNRTIs efavirenz, nevirapine...
Kavya Ramkumar,Nouri Neamati
Kavya Ramkumar
Introduction: The antiretroviral treatment paradigm for human immunodeficiency virus-1 (HIV-1) infection has undergone a significant change with the addition of a new class of therapeutic agents targeting HIV-1 integrase ...
Luigi Gennari,Daniela Merlotti,Vincenzo De Paola et al.
Luigi Gennari et al.
Introduction: Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. It is a common disorder in elderly subjects and represents a major public health problem, affect...
Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas [0.03%]
替莫唑胺治疗恶性星形细胞瘤疗效的证据评估
Ayman I Omar,Warren P Mason
Ayman I Omar
Introduction: Malignant gliomas are a heterogeneous group of primary central nervous system neoplasms that represent less than 2% of all cancers yet carry a significant burden to society. They are frequently associated wi...
Melissa Li-Ng,Joseph G Verbalis
Melissa Li-Ng
Introduction: The available treatment options for euvolemic and hypervolemic hyponatremia are limited, and consist mainly of fluid restriction, diuresis, or hypertonic solutions. Most of these therapies are neither well t...
Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy [0.03%]
度洛西汀在抑郁症治疗中的地位基于证据的评估
Daniel Z Lieberman,Suena H Massey
Daniel Z Lieberman
Introduction: Desvenlafaxine, the active metabolite of venlafaxine, is a serotonin norepinephrine reuptake inhibitor (SNRI) recently approved for the treatment of major depressive disorder. It is one of only three medicat...
Eptifibatide: The evidence for its role in the management of acute coronary syndromes [0.03%]
依替巴肽在急性冠脉综合征治疗中的作用证据分析
Ibrahim Shah,Shakeel O Khan,Surender Malhotra et al.
Ibrahim Shah et al.
Introduction: Acute coronary syndromes and non-Q-wave myocardial infarction are often initiated by platelet activation. Eptifibatide is a cyclic heptapeptide and is the third inhibitor of glycoprotein (Gp) IIb/IIIa that h...
Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer [0.03%]
阿西替尼治疗晚期甲状腺癌的潜力证据评估
Hari A Deshpande,Scott Gettinger,Julie Ann Sosa
Hari A Deshpande
Introduction: Thyroid cancer is a rare disease with an incidence of around 37,000 cases per year. However, its incidence is rising faster than many other cancers and for men this disease ranks highest overall in the rate ...
Indacaterol: a new once daily long-acting beta(2) adrenoceptor agonist [0.03%]
一种新的每日一次给药的长效β₂肾上腺素受体激动剂：茚达特罗
Kai M Beeh,Jutta Beier
Kai M Beeh
Introduction: Indacaterol is a novel once daily long-acting beta agonist (LABA) developed for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. ...